

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
10 November 2022 (10.11.2022)



(10) International Publication Number
WO 2022/235945 A1

(51) International Patent Classification:

A61K 47/55 (2017.01) A61K 31/53 (2006.01)
C07D 487/04 (2006.01) A61P 35/00 (2006.01)
C07D 495/00 (2006.01) A61P 35/02 (2006.01)
C07D 519/00 (2006.01) A61P 37/02 (2006.01)

(21) International Application Number:

PCT/US2022/027888

(22) International Filing Date:

05 May 2022 (05.05.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/184,439 05 May 2021 (05.05.2021) US

(71) Applicants: **BIOGEN MA INC.** [US/US]; 225 Binney Street, Cambridge, MA 02142 (US). **C4 THERAPEUTICS, INC.** [US/US]; 490 Arsenal Way, Suite #200, Watertown, MA 02472 (US).

(72) Inventors; and

(71) Applicants: **CHENG, Xinpeng** [CN/US]; 140 Arsenal St, Unit 2227, Watertown, MA 02472 (US). **HOPKINS, Brian T.** [US/US]; c/o Biogen MA Inc., 225 Binney Street, Cambridge, MA 02142 (US). **MARX, Isaac** [US/US]; c/o Biogen MA Inc., 225 Binney Street, Cambridge, MA 02142 (US). **NEVALAINEN, Marta** [US/US]; c/o Biogen MA Inc., 225 Binney Street, Cambridge, MA 02142 (US).



(72) Inventors: **GUCKIAN, Kevin M.**; c/o Biogen MA Inc., 225 Binney Street, Cambridge, MA 02142 (US). **STEFAN, Eric**; c/o Biogen MA Inc., 225 Binney Street, Cambridge, MA 02142 (US). **ANDERSON, Corey Don**; 24 N Crescent Circuit, Brighton, MA 02135 (US). **AHN, Jae Young**; 12 Bay State Ave #2, Somerville, MA 02144 (US). **O'SHEA, Morgan Welzel**; 91 Brewster Road, Waltham, MA 02451 (US). **YAP, Jeremy L.**; 8 Pinewood Ave, Sudbury, MA 01776 (US).

(74) Agent: **ZHANG, Xin** et al.; McCarter & English, LLP, 265 Franklin Street, Boston, MA 02110 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM,

(54) Title: COMPOUNDS FOR TARGETING DEGRADATION OF BRUTON'S TYROSINE KINASE

BTK—L—DSM (A)



(57) Abstract: This disclosure relates to compounds of Formula (A): BTK—L—DSM (A) or a pharmaceutically acceptable salt thereof, wherein DSM is a degradation signaling moiety that is covalently attached to the linker L, L is a linker that covalently attaches BTK to DSM, and BTK is a Btk binding moiety represented by Formula (I) or Formula (II) that is covalently attached to linker L; in which all of the variables are as defined in the application. Compounds or pharmaceutically acceptable salts thereof as described herein are capable of activating the selective ubiquitination of Btk proteins via the ubiquitin-proteasome pathways (UPP) and cause degradation of Btk proteins. The present disclosure also provides methods of treating disorders responsive to modulation of Btk activity and/or degradation of Btk with at least one compound described herein.

[Continued on next page]

AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))